SCHEMBL266680

SCHEMBL266680

CC(O)CN(Cc1cccc(C(=O)Nc2cc3ccccc3cc2C(=O)N/N=C\c2ccc(Cl)c(C(F)(F)F)c2)c1)CC(C)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 12/20 0.47
SLC34A1 Q06495 1/20 0.42
SLC34A3 Q8N130 1/20 0.42
SLC20A1 Q8WUM9 1/20 0.42
LMNA P02545 2/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ADCYAP1R1 P41586 4/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274036 1.00 SLC34A2 (0.47) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL266681 1.00 SLC34A2 (0.47) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL267705 0.90 SLC34A2 (0.50) SLC34A2SLC34A1SLC34A3SLC20A1MEN1
SCHEMBL273991 0.90 SLC34A2 (0.50) SLC34A2SLC34A1SLC34A3SLC20A1MEN1
SCHEMBL267704 0.90 SLC34A2 (0.50) SLC34A2SLC34A1SLC34A3SLC20A1MEN1
SCHEMBL269202 0.89 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL269203 0.89 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL274616 0.89 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL274245 0.88 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1LMNA
SCHEMBL268589 0.88 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885SLC34A1 4/4885SLC34A3 12/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.